FDA Calls Bay Area Zogenix’s Dravet Syndrome Drug a Breakthrough

Zogenix Announces Receipt of FDA Breakthrough Therapy Designation for ZX008 in Dravet Syndrome.

• Source: Biospace
• 507
• February 8, 2018